Therefore, we engineered TRuC-T cells targeting BCMA/CS1 by pairing two subunits of the TCR/CD3 complex to develop a more effective T cell therapy for multiple myeloma. This evidence concerns the gene SLAMF7 and plasma cell myeloma.